Del Mar Pharmaceuticals (Bc) Ltd.

Delmar Pharmaceuticals, Inc.

Anne Steinø

Dennis M Brown

Jeffrey A Bacha

Sandra Dunn

Methods for treating diffuse intrinsic pontine glioma (DIPG) comprising administration of a therapeutically effective amount of an alkylating hexitol (such as dianhydrogalacitol, diacetyldianhydrogalacitol, and dibromodulcitol) are disclosed. Such methods may further comprise administration of other anti-cancer agents. In preferred embodiments, the secondary anti-cancer agent is an inhibitor of Wee1 tyrosine kinase (such as adavosertib). Methods of treating malignancies in general comprising administration of a combination of an alkylating hexitol and an inhibitor of Wee1 tyrosine kinase are also disclosed.

Dianhydrogalactitol for the treatment of diffuse intrinsic pontine gliomas

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates Nmethylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.

Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates Nmethylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.

Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies

The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme. Dianhydrogalactitol acts as an alkylating agent on DNA that creates Nmethylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.

Growing community of inventors

Vancouver, Canada

Anne Steinø